Status:
COMPLETED
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
Lead Sponsor:
Pfizer
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
40+ years
Phase:
PHASE2
Brief Summary
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate. Patients will complete a series of questionnaire...
Eligibility Criteria
Inclusion
- Male subjects aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ≥13
- Clinical diagnosis of BPH.
- Qmax 5 to 15ml/sec with a voided volume of ≥150ml at visit 1 (screening).
Exclusion
- Urinary tract infection
- Primary neurological conditions affecting bladder function
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
609 Patients enrolled
Trial Details
Trial ID
NCT00457457
Start Date
May 1 2007
End Date
April 1 2008
Last Update
December 19 2018
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Herston, Queensland, Australia
2
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000
3
Pfizer Investigational Site
Brussels, Belgium, B-1090
4
Pfizer Investigational Site
Brussels, Belgium